NULISA™ Platform

Unlocking the Proteome

The NULISA™ Platform sets a new standard in proteomic analysis with attomolar sensitivity, allowing for unprecedented biomarker detection and quantitation.  

By leveraging a proprietary sequential immunocomplex capture and release mechanism and the latest advances in Next Generation Sequencing (NGS), the NULISA technology provides both ultra-high sensitivity and scalable multiplexing. 

ULTRA HIGH SENSITIVTY

Raising the Bar by
Lowering the Limit (of Detection)

Ultra-high attomolar sensitivity and lower limits of detection for the discovery and detection of critical biomarkers.  

BROAD DYNAMIC RANGE

Measuring Changes Across
the Biological Spectrum

With single plex up to 7 logs and multiplex up to 12 logs of dynamic range, NULISA enables quantitation across a broad range of biological expression levels without the need for dilution.

Validation

1-10s
Targets

Translation

10s-100s
Targets

Discovery

100s-1000s
Targets

FLEXIBLE PLEX

Scaling from Single-plex
to Multiplex

Flexible, scalable chemistry provides the ability to focus in on a single target, or multiplex hundreds to potentially thousands of targets in a single sample on one platform.

NULISA assays maintain performance from single qPCR to multiplex NGS analyses.

Fully Automated Workflow

Single-plex results in <8 hours and multiplex results in <15 hours with <30 minutes total hands-on time with the ARGO™ HT System

Single-plex Workflow

1
CREATE

Design run and
queue for ARGO

2
LOAD

Prep sample and
load instrument

3
RUN

High throughput sample-to results in <8 hours run time

4
ANALYZE

Integrated, cloud-based analytics

Multiplex Workflow

1
CREATE

Design run and
queue for ARGO

2
LOAD

Prep sample and
load instrument

3
RUN

High throughput sample to pooled NGS library in <8 hours run time

4
NGS

8 hour sequencing
run on illumina
systems

5
ANALYZE

Integrated, cloud-based analytics

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.